top of page

ANALYSIS OF GENE-EXPRESSION PROFILES

(n=5,096)

​

  • FOXC1 is specifically associated with BLBC.

  • FOXC1 is significantly over expressed in BLBC compared to other subtypes of breast cancer (P value < 0.0001).

  • No other gene was found to possess comparably strong correlation with BLBC.

  • FOXC1 is not expressed in normal breast tissue.

  • The level of FOXC1 expression correlates directly with overall survival.

​

​

​

​

​

​

​

​

​

​

​

​

​

Differential Expression of FOXC1 in Human Breast Cancer Subtypes

PROGNOSTIC SIGNIFICANCE OF FOXC1 IN BREAST CANCER

qRT-PCR RESULTS 

FOXC1 Is a Potential Prognostic Biomarker with Functional Significance in Basal-like Breast Cancer

Partha S. Ray, Jinhua Wang, Ying Qu, Myung-Shin Sim, Jaime Shamonki, Sanjay P.Bagaria, Xing Ye, Bingya Liu, David Elashoff, Dave S. Hoon, Michael A. Walter, John W.Martens, Andrea L. Richardson, Armando E. Giuliano and Xiaojiang Cui

Cancer Res May 15 2010 (70) (10) 3870-3876; DOI: 10.1158/0008-5472.CAN-09-4120

Clinical Study 5

AVISI0™ FOXC1 IHC

Clinical Study 5

​

AVISIO™ FOXC1 is a specific, stand alone, biomarker for BLBC and can specifically and accurately identify aggressive types (Luminal - Basal and Basal HER2)

  • 57 (=88%) of the 65 BLBC patients were correctly identified as AVISIO™ FOXC1 IHC positive (>4+)

  • 9  (= 23%) out of the 39 HER2 subtype patients were AVISIO™ FOXC1 IHC positive (>4+) indicating Basal - HER2 subtype 

    • ​15% - 29% of the HER2 subtype also express the basal - like subtype

  • 9 (=5%) out of 182 Luminal A subtype and 5 (7%) out of 69 Luminal B subtype patients were  ​​AVISIO FOXC1 IHC positive (>4+) indicating Luminal - Basal subtype

    • Up to 25% - 30% of the Luminal patients are known to express the basal - like subtype

​​

  • 20%-30% of BLBC subtype are positive for ER and/or HER2

  • 30% of ER+/PR+ tumors are ALSO FOXC1 positive

​

bottom of page